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Anti-inflammatory properties of a dual
PPARgamma/alpha agonist muraglitazar in in
vitro and in vivo models
Erja-Leena Paukkeri1, Tiina Leppänen1, Mira Lindholm1, Mun Fei Yam2, Mohd Zaini Asmawi2, Anne Kolmonen3,
Paula H Aulaskari3 and Eeva Moilanen1*
Abstract
Introduction: Peroxisome proliferator-activated receptor (PPAR) agonists are widely used drugs in the treatment of
diabetes and dyslipidemia. In addition to their metabolic effects, PPAR isoforms PPARa and PPARg are also involved
in the regulation of immune responses and inflammation. In the present study, we investigated the effects of a
dual PPARg/a agonist muraglitazar on inflammatory gene expression in activated macrophages and on
carrageenan-induced inflammation in the mouse.
Methods: J774 murine macrophages were activated by lipopolysaccharide (LPS) and treated with dual PPARg/a
agonist muraglitazar, PPARg agonist GW1929 or PPARa agonist fenofibrate. The effects of PPAR agonists on
cytokine production and the activation of inducible nitric oxide synthase (iNOS) pathway were investigated by
ELISA, Griess method, Western blotting and quantitative RT-PCR. Nuclear translocation, DNA-binding activity and
reporter gene assays were used to assess the activity of nuclear factor kappa B (NF-kB) transcription factor.
Carrageenan-induced paw oedema was used as an in vivo model of acute inflammation.
Results: Muraglitazar as well as PPARg agonist GW1929 and PPARa agonist fenofibrate inhibited LPS-induced iNOS
expression and NO production in activated macrophages in a dose-dependent manner. Inhibition of iNOS
expression by muraglitazar included both transcriptional and post-transcriptional components; the former being
shared by GW1929 and the latter by fenofibrate. All tested PPAR agonists also inhibited IL-6 production, while
TNFa production was reduced by muraglitazar and GW1929, but not by fenofibrate. Interestingly, the anti-
inflammatory properties of muraglitazar were also translated in vivo. This was evidenced by the finding that
muraglitazar inhibited carrageenan-induced paw inflammation in a dose-dependent manner in mice as did iNOS
inhibitor L-NIL and anti-inflammatory steroid dexamethasone.
Conclusions: These results show that muraglitazar has anti-inflammatory properties both in vitro and in vivo and
these effects reflect the agonistic action through both PPARa and PPARg.
Introduction
It has long been known that macrophages are pivotal cells
in the pathogenesis of autoimmune diseases, including
rheumatoid arthritis [1,2]. During the last decades macro-
phages have also been found to affect metabolism in
various tissues and today it is widely agreed that macro-
phages are also associated with the pathophysiology of
many obesity-linked diseases [3-5]. The mechanisms
connecting macrophage activation and metabolism are not
fully known but some hypotheses have been proposed.
Macrophages are present in adipose tissue and when
aberrantly activated in relation to obesity they produce
inflammatory factors by themselves and also activate sur-
rounding adipocytes to release signalling proteins called
adipokines. Adipokines are known to regulate energy
metabolism and appetite but also inflammatory responses,
arthritis and catabolic processes in articular cartilage [6]. It
is also obvious that obesity-related changes in energy
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metabolism directly regulate macrophage responses [7].
From the pharmacological point of view, an interesting
question exists of if or how the macrophage phenotype
and secretory profile differ between chronic inflammation
typical, for example, in rheumatoid arthritis and obesity-
related systemic inflammation, and if the same known and
future anti-inflammatory compounds would have thera-
peutic value in only one or both of those inflammatory
conditions.
Peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear receptor superfamily and
they are strongly linked to the regulation of energy
homeostasis in cells. PPARs are expressed in three iso-
forms: PPARa, PPARg and PPARb/δ. PPARg agonists
thiazolidinediones (TZDs) and PPARa agonist fibrates
are widely used as pharmacological agents in the treat-
ment of diabetes and dyslipidemia, respectively. Although
the main interest in PPAR-related studies has been
focused on the role of PPARs in energy homeostasis,
PPARs, especially PPARa and PPARg, are also shown to
be involved in the regulation of the immune and inflam-
matory responses in obesity-linked diseases [8-10].
During the last few years some reports have been pub-
lished showing that PPARg agonists reduce inflammatory
responses in animal models of rheumatoid arthritis [11].
Nevertheless, we found only a single study suggesting
that also a PPARa agonist fenofibrate would have anti-
inflammatory effects in experimentally induced arthritis
[12].
Muraglitazar is a dual PPARg/a-agonist that has
strong PPARg and moderate PPARa effects [13]. Origin-
ally, it was developed for the treatment of type II dia-
betes with a view to combining both insulin sensitizing
and antihyperlipidemic effects of the PPAR agonists.
Muraglitazar has been shown to decrease the levels of
HbA1c, FFA and triglycerides and to increase the levels
of HDL in humans when compared to placebo, and it
appeared to be more potent than pioglitazone [14,15].
However, despite the fact that there are several reports
on the antidiabetic effects of muraglitazar, there are no
previous studies on the effects of muraglitazar in inflam-
matory processes.
In the present study, we aimed to investigate the anti-
inflammatory effects of muraglitazar. Since the immunore-
gulatory effects of PPARa and PPARg are somewhat dif-
ferent, we wanted to study whether muraglitazar has more
potent anti-inflammatory effects than PPARg or PPARa
agonists alone. To examine this we investigated the effects
of muraglitazar on the activation of the inducible nitric
oxide synthase (iNOS) pathway and on the production of
inflammatory cytokines in activated macrophages. We
extended our study by testing the effect of muraglitazar on
carrageenan-induced paw inflammation in the mouse.
Materials and methods
Materials
Reagents were obtained as follows: GW1929 and
MG132 from Tocris Bioscience (Bristol, UK), N6-(1-imi-
noethyl)-L-lysine (L-NIL) from Enzo Life Sciences Ltd.
(Exeter, UK), rabbit polyclonal b-actin, lamin A/C and
iNOS antibodies and goat HRP-conjugated anti-rabbit
polyclonal antibody from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). Nuclear factor kappa B (NF-B)
subunit p65 antibody was from Cell Signaling Technol-
ogy Inc. (Danvers, MA, USA). Muraglitazar was synthe-
sised in the laboratory of Dr. Paula H. Aulaskari
(University of Eastern Finland, Joensuu Campus, Joen-
suu, Finland), see below. Other reagents were from
Sigma-Aldrich Co. (St. Louis, MO, USA).
Muraglitazar was synthesised by a five-step procedure
according to Devasthale et al. [13]. The structure and pur-
ity of intermediates and the final product muraglitazar
were confirmed by melting point analysis (Gallenkamp
melting point apparatus MFB-595, Gallenkamp, Lough-
borough, UK), 1H, 13C NMR spectroscopy (Bruker Avance
250 MHz and 400 MHz spectrometer, Bruker BioSpin
AG, Fällanden, Switzerland) using deuteriumchloroform
as a solvent and tetramethylsilane as a reference, and by
IR spectroscopy (Nicolet Avatar 320 FT-IR spectrometer,
Thermo Electron Scientific Instruments, LLC, Madison,
WI, USA) using dry potassium bromide as a salt compo-
nent of solid mixture. The molecular structure and the
purity of muraglitazar were also confirmed by mass spec-
trometer and elemental analysis. The mass spectrometer
measurements were performed on Bruker BioAPEX II 47e
Fourier transform ion cyclotron resonance (FTICR) mass
spectrometer (Bruker Daltonics, Billerica, MA, USA)
equipped with an InfinityTM cell, 4.7 Tesla 160-mm-bore
superconducting magnet (Magnex Scientific Ltd., Abing-
don, UK), and an external electron ionization (EI) or elec-
trospray ion source (ESI) (Analytica of Branford Inc.,
Branford, CT, USA). Elemental analysis was performed on
CE Instruments EA 1110 elemental analyser (CE Instru-
ments Ltd., Rodano, MI, Italy). The results of elemental
analysis were within ± 0.2% of the theoretical values.
Cell culture
Murine J774 macrophages (American Type Culture Col-
lection, Manassas, VA, USA) were cultured at 37°C in
5% CO2 atmosphere in Dulbecco’s modified Eagle’s
medium with Ultraglutamine 1 (Lonza Group Ltd.,
Basel, Switzerland) supplemented with 10% heat-inacti-
vated foetal bovine serum (Lonza Group Ltd), 100 U/ml
penicillin, 100 µg/ml streptomycin and 250 ng/ml
amphotericin B (Invitrogen Co., Carlsbad, CA, USA)
and harvested with trypsin-EDTA (Invitrogen Co.). Cells
were seeded on 24-well plates for RNA extraction and
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nitrite and ELISA measurements, on 24-well plates or 6-
well plates for preparation of cell lysates for Western
blotting, on 10 cm dishes for preparation of nuclear
extracts for Western blotting and NF-B p65 DNA
binding assay and on 96-well plates for an XTT test.
Confluent cultures were exposed to fresh culture med-
ium containing the compounds of interest.
Human HEK293 cells (American Type Culture Collec-
tion) were cultured at 37°C in 5% CO2 atmosphere in
Eagle’s minimal essential medium (Lonza Group Ltd.)
supplemented with 0.15% sodium bicarbonate, 100 µM
non-essential aminoacids, 1 mM sodium pyruvate, 10%
heat-inactivated foetal bovine serum (Lonza Group Ltd),
100 U/ml penicillin, 100 µg/ml streptomycin and 250 ng/ml
amphotericin B (Invitrogen Co.) and harvested with trypsin-
EDTA (Invitrogen Co.). Cells were seeded on 24-well plates
for RNA extraction. Confluent cultures were exposed to
fresh culture medium containing the compounds of
interest.
Cell viability after treatment with combinations of LPS
or cytokine mixture and the tested compounds was
assessed by modified XTT test (Cell Proliferation Kit II,
Roche Diagnostics, Mannheim, Germany) according to
the manufacturer’s instructions.
Preparation of stable J774-pGL4(miNOS-prom)neo and
HEK293-pNF-B(luc)neo reporter cell lines
The pGL-MNOS II-5’-Luc plasmid [16] containing 5’-
flanking sequence (1,171 bp, positions -1,570 to +141;
promoter and a part of exon 1) of the murine iNOS gene
was provided by Professor Harmut Kleinert (Johannes
Gutenberg University, Mainz, Germany). This plasmid
was digested with KpnI and HindIII, and the restriction
fragment, containing murine iNOS promoter and part of
exon 1, was then cloned into the KpnI/HindIII site of
firefly luciferase reporter plasmid pGL4.17(luc2/neo)
(Promega, Madison, WI, USA) generating pGL4(miNOS-
prom)neo, in which the luciferase gene is driven by
murine iNOS promoter. The plasmid was sequenced to
confirm the appropriate size, position and orientation of
the insert in the plasmid. To create a stable transfection
with murine iNOS promoter reporter plasmid, J774 cells
were transfected with pGL4(miNOS-prom)neo using
Lipofectamine 2000 (Invitrogen Co.) according to the
manufacturer’s instructions. Transfected cells were
selected with G418 disulfate salt (Sigma-Aldrich Co.)
treatment (800 µg/ml). After the selection, the survived
clones were pooled to give rise to J774-pGL4(miNOS-
prom)neo cell line and further cultured in the presence
of 400 µg/ml of G418.
To create a stable transfection with NF-B reporter
plasmid, HEK293 cells were transfected with pGL4.32
[luc2P/NF-B-RE/Hygro] (Promega) using Lipofectamine
2000 (Invitrogen Co.) according to the manufacturer’s
instructions. Transfected cells were selected with hygro-
mycin B (EMD Biosciences Inc., La Jolla, CA, USA) treat-
ment (200 µg/ml). After the selection, the survived clones
were pooled to give rise to HEK293- pGL4.32[luc2P/NF-
B-RE/Hygro] cell line and further cultured in the pre-
sence of 100 µg/ml of hygromycin B.
Nitrite determination
Nitrous oxide (NO) production was determined by mea-
suring the accumulation of nitrite, a stable metabolite of
NO in aqueous condition, into the culture medium. The
culture medium was collected at indicated time points
and nitrite was measured by the Griess reaction [17].
Preparation of cell lysates for Western blotting
At indicated time points, the cells were rapidly washed
with ice-cold phosphate-buffered saline and solubilized
in cold lysis buffer containing 10 mM Tris-base, pH 7.4,
5 mM EDTA, 50 mM NaCl, 1% Triton X-100, 0.5 mM
phenylmethylsulphonyl fluoride, 1 mM sodium orthova-
nadate, 20 μg/ml leupeptin, 50 μg/ml aprotinin, 5 mM
NaF, 2 mM sodium pyrophosphate and 10 μM n-octyl-b-
D-glucopyranoside. After incubation on ice for 15 min-
utes, lysates were centrifuged (13,400 g, 4°C, 10 minutes),
supernatants were collected and mixed 3:1 with SDS
sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol,
2% SDS, 0.025% bromophenol blue and 5% b-mercap-
toethanol). The samples were stored at -20°C until ana-
lysed. An aliquot of the supernatant was used to
determine protein concentration by the Coomassie blue
method [18].
Preparation of nuclear extracts for Western blotting
At indicated time points, the cells were rapidly washed
with ice-cold phosphate-buffered saline and solubilized in
hypotonic buffer A (10 mM HEPES-KOH, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM phe-
nylmethylsulphonyl fluoride, 1 mM sodium orthovanadate,
10 μg/ml leupeptin, 25 μg/ml aprotinin, 1 mM NaF and
0.1 mM EGTA). After incubation on ice for 10 minutes,
the cells were vortexed for 30 seconds and the nuclei were
separated by centrifugation at 4°C, 21,000g for 10 seconds.
Nuclei were resuspended in buffer C (20 mM HEPES-
KOH, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM
MgCl2, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsul-
phonyl fluoride, 1 mM sodium orthovanadate, 10 μg/ml
leupeptin, 25 μg/ml aprotinin, 1 mM NaF and 0.1 mM
EGTA) and incubated on ice for 20 minutes. Nuclei were
vortexed for 30 seconds and nuclear extracts were obtained
by centrifugation at 4°C, 21,000 g for 2 minutes. Superna-
tants were collected and mixed 3:1 with SDS sample buffer.
The samples were stored at -70°C until analysed. Coomas-
sie blue method was used to measure the protein content
of the samples [18].
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Western blotting
Prior to Western blotting, samples were boiled for 10
minutes and 20 μg of protein was loaded per lane on
10% or 12% SDS-polyacrylamide gels and separated by
electrophoresis. Proteins were transferred to Hybond
enhanced chemiluminescence nitrocellulose membrane
(GE Healthcare, Little Chalfont, Buckinghamshire, UK).
After the transfer, the membrane was blocked in TBS/T
(20 mM Tris-base pH 7.6, 150 mM NaCl, 0.1% Tween-
20) containing 5% of non-fat dry milk or 5% bovine
serum albumin at room temperature for one hour and
incubated with primary antibody in the blocking solu-
tion at 4°C overnight. The membrane was washed with
TBS/T, incubated with secondary antibody in the block-
ing solution at room temperature for one hour and
washed. Bound antibody was detected using SuperSignal
West Pico or Dura chemiluminescent substrate (Pierce,
Rockford, IL, USA) and ImageQuant LAS 4000 mini
imaging system (GE Healthcare). The chemiluminescent
signal was quantified with ImageQuant TL 7.0 image
analysis software.
RNA extraction and quantitative real-time PCR
At the indicated time points, culture medium was
removed and total RNA of the cultured cells was extracted
using GenElute™ Mammalian Total RNA Miniprep kit
(Sigma-Aldrich Co.). For luciferase mRNA experiments,
total RNA was treated with DNase I (Fermentas UAB,
Vilnius, Lithuania). Total RNA (100 ng) was reverse-
transcribed to cDNA using TaqMan Reverse Transcrip-
tion reagents and random hexamers (Applied Biosystems,
Foster City, CA, USA). cDNA obtained from the reverse
transcription reaction was diluted 1:20 with RNase-free
water and was subjected to quantitative PCR using Taq-
Man Universal PCR Master Mix and ABI Prism 7000
sequence detection system (Applied Biosystems).
Total RNA of the tissue samples was extracted by
GenElute™ Mammalian Total RNA Miniprep kit with
proteinase K digestion (Sigma-Aldrich Co.). Total RNA
(500 ng) was reverse-transcribed to cDNA using Max-
ima First Strand cDNA Synthesis Kit (Fermentas UAB).
cDNA obtained from the reverse transcription reaction
was diluted 1:20 with RNase-free water and was sub-
jected to quantitative PCR using TaqMan Universal
PCR Master Mix and ABI Prism 7000 sequence detec-
tion system (Applied Biosystems).
Primers and probes for luciferase, IL-6, iNOS and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) (Table 1)
were optimized according to the manufacturer’s instruc-
tions in TaqMan Universal PCR Master Mix Protocol part
number 4304449 revision C. The expression of mouse
TNFa mRNA was measured by using TaqMan® Gene
Expression Assay (Mm00443260_g1, Applied Biosystems,
Foster City, CA, USA).
PCR reaction parameters were as follows: incubation
at 50°C for 2 minutes, incubation at 95°C for 10 min-
utes, and thereafter 40 cycles of denaturation at 95°C
for 15 s and annealing and extension at 60°C for 1 min-
ute. Each sample was determined in duplicate.
The relative mRNA levels were quantified and compared
using the relative standard curve method as described in
Applied Biosystems User Bulletin number 2.
NF-B p65 DNA binding assay
DNA binding activity of NF-B p65 was evaluated using
NF-B (p65) Transcription Factor Assay Kit (Cayman
Chemical Company, Ann Arbor, MI, USA). The nuclear
extracts for the assay were prepared according to the man-
ufacturer’s instructions and 10 µg of nuclear protein per
well was used for the experiment. The samples were incu-
bated at +4°C overnight with the dsDNA templates carry-
ing NF-B response element. After primary (anti-NF-B
p65) and secondary (goat anti-rabbit HRP) antibody treat-
ments, developing reagents were added and absorbance
was read at 450 nm.
Enzyme-Linked Immunosorbent Assay (ELISA)
Culture medium samples were kept at -20°C until
assayed. The concentrations of IL-6 and TNFa in cul-
ture medium were determined by ELISA according to
the manufacturer’s instructions (R&D Systems Europe,
Abingdon, UK).
Carrageenan-induced paw oedema in the mouse
Prior to the experiment investigating the time dependent
formation of carrageenan-induced paw oedema, 36 male
Charles River mice (weighing 25.0 to 30.0 g) were housed
Table 1 Primer and probe sequences.
Gene Oligonucleotide Sequence 5’ ® 3’
Human
GAPDH
Forward primer TCCTACCACCAGCAACCCTGCCA
Reverse primer GCAACAATATCCACTTTACCAGAGTTAA
Probe CGCCTGGTCACCAGGGCTGC
Luciferase Forward primer ACGGCTTCGGCATGTTCA
Reverse primer CTCCTCCTCGAAGCGGTACA
Probe TTGATCTGCGGCTTTCGGGTCGT
Mouse
GAPDH
Forward primer GCATGGCCTTCCGTGTTC
Reverse primer GATGTCATCATACTTGGCAGGTTT
Mouse IL-6 Probe TCGTGGATCTGACGTGCCGCC
Forward primer TCGGAGGCTTAATTACACATGTTC
Reverse primer CAAGTGCATCATCGTTGTTCATAC
Probe CAGAATTGCCATTGCACAACTCTTTTCTCA
Mouse
iNOS
Forward primer CCTGGTACGGGCATTGCT
Reverse primer GCTCATGCGGCCTCCTT
Probe CAGCAGCGGCTCCATGACTCCC
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and cared for under the guidelines of the institutional ani-
mal care and use committee with food and water provided
ad libitum. The study was approved by the Animal Ethic
Committee, Universiti Sains Malaysia.
The animals were randomly divided into six groups
(six mice per group) and each group was treated orally
with the test compound suspended in 2.0% (w/v) car-
boxymethyl cellulose (CMC) in distilled water. The test
groups were as follows: control (treated with 2.0% CMC
only), muraglitazar 12.5 mg/kg, muraglitazar 25 mg/kg,
muraglitazar 50 mg/kg, L-NIL 50 mg/kg and dexa-
methasone 2 mg/kg. An hour after the treatment, 40 µl
of carrageenan (1% suspension in normal saline) was
injected subcutaneously into the left hind paws of the
animals. Thicknesses of the paws were measured by
micrometer one hour before and one hour, four hours
and six hours after the carrageenan injection. The
results are expressed as percentages of swelling calcu-
lated as follows:
Difference = (thickness of the hind paw at indicated time point − thickness of the hind
paw before carrageenan)/thickness of the hind paw before carrageenan.
The carrageenan-induced gene expression was investi-
gated in C57BL/6 mice. The study was approved by the
Animal Care and Use Committee of the University of
Tampere and the respective provincial committee for
animal experiments. Animals were housed under stan-
dard conditions of light, temperature and humidity
(12:12 h light-dark cycle, 22 ± 1°C, 50 to 60%) with food
and water provided ad libitum.
Mice were randomly divided into two study groups with
five and seven mice in the groups and muraglitazar 50 mg/
kg was injected intraperitoneally into the group of five
mice. Two hours after the treatment, the mice were
anesthetized with an intraperitoneal injection of 0.5 mg/kg
of medetomidine (Orion Oyj, Espoo, Finland) and 75 mg/
kg of ketamine (Pfizer Oy Animal Health, Helsinki,
Finland), and 30 µl of l-carrageenan (1.5% suspension in
normal saline) was injected subcutaneously into a hind paw
of the animals. As a control, 30 µl of saline was injected
into the contralateral paws. The paw volumes were mea-
sured before and six hours after carrageenan injection by
plethysmometer (Ugo Basile Srl, Comerio, Italy). Oedema is
expressed as the difference between the change in carragee-
nan-treated paw volume and the control paw volume in µl.
After six hours of carrageenan injection, the mice were
sacrificed by cervical dislocation. Carrageenan-treated and
control paws were skinned and the soft tissues of the paws
were collected and RNA was extracted as described above.
Statistics
Results are expressed as mean + standard error of mean
(SEM). When indicated, statistical significance was cal-
culated by analysis of variance followed by Dunnett’s
multiple comparisons test or Mann-Whitney test. Differ-
ences were considered significant at P <0.05.
Results
Muraglitazar and PPARa and PPARg agonists decreased
NO production and iNOS expression
Resting J774 macrophages did not produce detectable
amounts of NO, but when the cells were activated
through TLR4 pathway by bacterial endotoxin LPS, NO
production and iNOS expression were increased. Mura-
glitazar, PPARa agonist fenofibrate and PPARg agonist
GW1929 decreased LPS-induced iNOS expression
(Figure 1) and NO production (Figure 2) in a dose-
dependent manner. Muraglitazar, fenofibrate or GW1929
did not affect cell viability at the concentration used as
determined by XTT test.
Muraglitazar and a PPARg agonist, but not a PPARa
agonist, reduced iNOS mRNA expression
Since all three PPAR agonists decreased iNOS expres-
sion and NO production, we went further and deter-
mined the effects of PPAR agonists on iNOS mRNA
expression. Muraglitazar and GW1929 reduced the
levels of iNOS mRNA when determined six hours after
the addition of LPS. However, fenofibrate had no effect
on iNOS mRNA levels as compared to the cells treated
with LPS only. NF-B inhibitor MG132 was used as a
control compound and it reduced LPS-induced iNOS
mRNA levels as expected (Figure 3a).
Since the reduction of iNOS mRNA levels may be a
sign of either transcriptional inhibition or increase in
iNOS mRNA degradation, we studied the effect of
PPAR agonists on the half-life of iNOS mRNA. After
six-hour incubation with LPS alone or together with
PPAR agonists, actinomycin D was added to the cells to
stop mRNA synthesis. Incubations were terminated at
different time points after the addition of actinomycin
D. None of the PPAR agonists did affect the stability of
iNOS mRNA when compared to the cells treated with
LPS only (Figure 3b). These results suggest that the sup-
pressive effect of muraglitazar and GW1929 on LPS-
induced iNOS mRNA levels is mediated at the level of
iNOS transcription.
We further investigated the effect of muraglitazar on the
activity of iNOS promoter in J774 macrophages stably
transfected to express luciferase reporter gene under the
control of full length murine iNOS promoter. Similar to
the effects on iNOS mRNA levels in wild-type J774 cells,
muraglitazar and GW1929, but not fenofibrate, reduced
LPS-induced iNOS promoter activity (Figure 3c).
The different effects of fenofibrate and GW1929 on
iNOS mRNA expression may be explained by our pre-
vious findings that PPARa agonists regulate iNOS
expression at the post-transcriptional level [19]. To
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study the post-transcriptional effects of muraglitazar and
the other two PPAR agonists on iNOS protein levels, we
first stimulated J774 macrophages with LPS for 10
hours, and PPAR agonists were added thereafter for 14
hours. Muraglitazar and fenofibrate, but not GW1929,
were able to reduce iNOS protein levels in these post-
transcriptional time points (Figure 3d).
Effects of muraglitazar and PPARa and PPARg agonists
on TNFa and IL-6 production
In order to investigate if PPAR agonists regulate the
expression of other genes related to innate immunity,
we measured their effects on IL-6 and TNFa produc-
tion. LPS induced TNFa and IL-6 production in J774
cells when measured with ELISA in the culture medium
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Figure 1 Effects of PPAR agonists on iNOS protein expression in J774 macrophages. Cells were stimulated with lipopolysaccharide (LPS)
and treated with increasing concentrations of fenofibrate (a), muraglitazar (b) or GW1929 (c). After 24 h incubation, proteins were extracted and
the levels of inducible nitric oxide synthase (iNOS) protein were analysed by Western blotting. b-actin was used as a loading control. Results
represent the mean + SEM of three experiments, from which one representative Western blot is shown. *P <0.05 and **P <0.01 as compared to
cells treated with LPS alone.
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after 24 hours incubation. All the agonists reduced IL-6
production in a dose-dependent manner (Figure 4).
However, LPS-induced TNFa production was reduced
only by GW1929 and muraglitazar at the highest con-
centration used (Figure 5c, b). Fenofibrate, on the other
hand, tended to increase TNFa production at higher
concentrations (Figure 5a).
Muraglitazar or PPARa or PPARg agonists had no effect
on NF-B activation
As we have reported in this paper, muraglitazar reduces
the synthesis of iNOS, IL-6 and TNFa. The syntheses of
all these inflammatory markers are regulated by tran-
scription factor NF-B [20,21]. Therefore, we hypothe-
sized that muraglitazar might affect the activity of NF-
B.
To test this, we first investigated the effect of muragli-
tazar on the nuclear translocation of NF-B. LPS
enhanced the nuclear translocation of NF-B peaking at
30 minutes of stimulation. Muraglitazar, fenofibrate or
GW1929 did not affect the nuclear levels of NF-B p65
when compared to cells treated with LPS only (Figure
6a).
We continued by studying whether PPAR agonists
affect the DNA binding activity of NF-B. As illustrated
in Figure 6b, muraglitazar, fenofibrate or GW1929 did
not reduce the ability of NF-B to bind to dsDNA frag-
ments containing NF-B response element. NF-B inhi-
bitor pyrrolidine dithiocarbamate (PDTC) was used as a
positive control compound and it reduced LPS-induced
NF-B binding as expected.
Further, we evaluated the effect of PPAR agonists on
NF-B -mediated transcription using HEK293 cells sta-
bly transfected with a luciferase reporter gene under the
control of NF-B-responsive promoter. PPAR agonists
did not modulate NF-B-mediated transcription while
NF-B inhibitor PDTC had an effect as expected (Figure
6c).
Muraglitazar reduced carrageenan-induced inflammatory
responses in the mouse
To determine if the anti-inflammatory properties of
muraglitazar are also translated to in vivo situations, we
examined the effect of muraglitazar on carrageenan-
induced inflammatory paw oedema in mice. Muraglita-
zar prevented the development of oedema in a dose-
dependent manner (Figure 7). With the highest dose of
muraglitazar (50 mg/kg) used, carrageenan-induced
oedema was reduced by 54% at the six-hour time point.
Dexamethasone 2 mg/kg and iNOS inhibitor L-NIL 50
mg/kg were used as control compounds and they
reduced the oedema by 69% and 48%, respectively.
In the following series of experiments, we analysed the
effect of muraglitazar on inflammatory gene expression
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Figure 2 Effects of PPAR agonists on NO production in J774
macrophages. Cells were stimulated with lipopolysaccharide (LPS)
and treated with increasing concentrations of fenofibrate (a),
muraglitazar (b) or GW1929 (c). After 24 h incubation, nitrite
accumulated into the culture medium was measured by Griess
reaction as a marker of nitric oxide (NO) production. Results
represent the mean + SEM (n = 6). **P <0.01 as compared to cells
treated with LPS alone.
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Figure 3 Effects of PPAR agonists on iNOS expression in activated J774 macrophages. (a) Effects of peroxisome proliferator-activated
receptor (PPAR) agonists on inducible nitric oxide synthase (iNOS) mRNA expression. Cells were treated with PPAR agonists, NF-B inhibitor
MG132 or vehicle (dimethyl sulfoxide, DMSO) and stimulated with LPS for six hours. Total RNA was extracted and iNOS mRNA was determined
by RT-PCR. The results were normalized against GAPDH mRNA. (b) Effects of PPAR agonists on iNOS mRNA degradation. Cells were treated with
PPAR agonists or vehicle (DMSO) and stimulated with lipopolysaccharide (LPS). After six hours incubation, actinomycin D (1 µg/ml) was added to
the cell culture to stop transcription. Total RNA was extracted at indicated time points after actinomycin D addition, and iNOS mRNA was
determined by RT-PCR. The results were normalized against GAPDH mRNA. (c) Effects of PPAR agonists on iNOS promoter activity in J774
macrophages stably transfected with a luciferase (LUC) reporter gene under the control of iNOS protein. Cells were treated with PPAR agonists,
NF-B inhibitor MG132 or vehicle (DMSO) and stimulated with LPS for six hours. Total RNA was extracted and LUC mRNA was determined by
RT-PCR. The results were normalized against GAPDH mRNA. (d) Post-transcriptional effects of PPAR agonists on iNOS protein levels. Cells were
stimulated with LPS for 10 hours. After the stimulation, the culture medium was changed and the cells were further incubated with PPAR
agonists or vehicle (DMSO) without LPS for additional 14 hours. Then, proteins were extracted and the levels of iNOS protein were analysed by
Western blotting. b-actin was used as a loading control. Results represent the mean + SEM (n = 3 to 4). In d one representative Western blot is
shown. *P <0.05 and **P <0.01 as compared to cells treated with LPS alone.
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Figure 4 Effects of PPAR agonists on IL-6 production in J774
macrophages. Cells were treated with increasing concentrations of
fenofibrate (a), muraglitazar (b) or GW1929 (c) and stimulated with
lipopolysaccharide (LPS). After 24 h incubation, IL-6 accumulated
into the culture medium was measured by ELISA. Results represent
the mean + SEM (n = 4). *P <0.05 and **P <0.01 as compared to
cells treated with LPS alone.
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Figure 5 Effects of PPAR agonists on TNFa production in J774
macrophages. Cells were treated with increasing concentrations of
fenofibrate (a), muraglitazar (b) or GW1929 (c) and stimulated with
lipopolysaccharide (LPS). After 24 h incubation, TNFa accumulated
into the culture medium was measured by ELISA. Results represent
the mean + SEM (n = 4). *P <0.05 and **P <0.01 as compared to
cells treated with LPS alone.
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Figure 6 Effects of PPAR agonists on NF-B activation and NF-B-mediated transcription. (a) Effects of peroxisome proliferator-activated
receptor (PPAR) agonists on NF-B translocation to nucleus. J774 cells were preincubated with PPAR agonists or vehicle (dimethyl sulfoxide,
DMSO) for two hours before addition of lipopolysaccharide (LPS). After 30 minutes incubation with LPS, nuclear extracts were prepared. The
levels of NF-B p65 in nuclear extracts were analysed by Western blotting. Lamin A/C was used as a loading control. (b) Effects of PPAR agonists
on DNA binding activity of NF-B. J774 cells were preincubated with PPAR agonists, NF-B inhibitor pyrrolidine dithiocarbamate (PDTC) or
vehicle (DMSO) for two hours before addition of LPS. After one hour incubation with LPS, nuclear extracts were prepared and the binding
activity of NF-B p65 to DNA was analysed as described in methods. (c) Effects of PPAR agonists on NF-B-mediated transcription activity.
HEK293 cells were stably transfected with a luciferase (LUC) reporter gene under the control of NF-B-responsive promoter. The cells were
preincubated with PPAR agonists, NF-B inhibitor PDTC or vehicle (DMSO) for two hours before addition of TNFa. After six hours’ incubation
with TNFa, total RNA was extracted and LUC mRNA was determined by RT-PCR. The LUC mRNA levels were normalized against GAPDH mRNA.
Results represent the mean + SEM (n = 3 to 4). In a one representative Western blot is shown. **P <0.01 as compared to cells treated with LPS
or TNFa alone.
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in carrageenan-induced inflammation. In line with the
previous series, muraglitazar attenuated carrageenan-
induced paw oedema (Figure 8a). Muraglitazar also
decreased the levels of IL-6, TNFa and iNOS mRNA by
80%, 54% and 64%, respectively (Figure 8b-d).
Discussion
The present findings show that muraglitazar has anti-
inflammatory properties both in in vitro and in vivo mod-
els. The results suggest that the anti-inflammatory effects
of muraglitazar reflect the agonistic action through both
PPARa and PPARg. To our knowledge, this is the first
report describing the effects of dual PPARg/a agonists on
inflammatory responses.
In support of the present findings, previous reports also
describe the inhibitory effects of PPARg or PPARa
agonists on inflammatory mediators in cell culture experi-
ments [22]. PPARg and PPARa ligands have been reported
to decrease plasma levels of proinflammatory cytokines in
diabetic and hyperlipidemic patients [23]. In our experi-
ments, PPARa and PPARg agonists had somewhat differ-
ent effects on IL-6, TNFa and iNOS expression. All the
agonists reduced IL-6 production in a similar potency.
However, fenofibrate was not able to decrease TNFa pro-
duction or iNOS mRNA levels, contrary to the effects of
GW1929 or muraglitazar. On the other hand, unlike
GW1929, muraglitazar and fenofibrate were able to
decrease iNOS protein levels still at post-transcriptional
time points. This suggests that activation of PPARa and
PPARg regulate different pathways in the LPS-activated
inflammatory cascades. The effects of PPAR agonists on
iNOS expression are supported by our previous findings
showing that PPARa agonists WY14643 and GW7647
regulate iNOS expression by enhancing its degradation
[19]. The present results imply that the effect of muraglita-
zar on TNFa production is mediated by the PPARg
component of action and on IL-6 production and iNOS
expression by both PPARa and PPARg components of
action. Especially, as for the inhibition of iNOS expression,
muraglitazar seems to be a more potent inhibitor than
fenofibrate or GW1929 alone. This is explained by the
findings that PPARg (but not PPARa) activation inhibits
iNOS transcription and PPARa (but not PPARg) activa-
tion has an effect at post-transcriptional level, while mura-
glitazar (as expected) has both of those effects. Thus the
results suggest that combining the effects of PPARa and
PPARg by using a dual PPARg/a agonist results in
improved anti-inflammatory action as compared to
PPARa or PPARg agonists alone.
In the present study, muraglitazar reduced iNOS mRNA
expression and promoter activity but did not affect the
activity of NF-B, which is an important transcription fac-
tor for iNOS and IL-6 genes. According to our preliminary
experiments, muraglitazar did not affect the activation of
STAT1 or IRF1 either. Although the activity of NF-B
was not altered, it is possible that muraglitazar regulates
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Figure 7 Effect of muraglitazar on carrageenan-induced paw oedema in the mouse. Muraglitazar, inducible nitric oxide synthase (iNOS)
inhibitor L-NIL, dexamethasone or vehicle (2.0% CMC) were given to animals per os 1 hour prior to carrageenan injection (1%). Paw oedema
was measured before and one, four and six hours after carrageenan injection by micrometer. Oedema is expressed as increase in paw thickness
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mice treated with carrageenan alone.
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the transcription machinery in a more complicated man-
ner. Still, further studies are needed to uncover the
detailed target of muraglitazar in the transcriptional acti-
vation of iNOS.
There is evidence suggesting that PPARg and PPARa
agonists attenuate experimentally induced arthritis in
murine models. Tomita et al. [24] and Sumariwalla
et al. [25] showed that PPARg agonists THR0921 and
CLX-090717, respectively, reduced clinical signs of syno-
vitis in collagen-induced arthritis in the mouse.
THR0921 also decreased the circulating levels of IgG
antibody to the collagen used in immunization [24].
Koufany et al. [26] reported that thiazolidinediones rosi-
glitazone and pioglitazone reduced synovial expression
of TNFa, IL-1b and basic fibroblast growth factor and
clinical signs of synovitis in Freund’s adjuvant-induced
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Figure 8 Effect of muraglitazar on carrageenan-induced production of inflammatory mediators in the mouse. Muraglitazar was
administrated to animals intraperitoneally two hours prior to carrageenan injection (1.5%). (a) Paw oedema was measured before and six hours
after carrageenan injection by plethysmometer. Oedema is expressed as difference between carrageenan-treated paw and control paw. (b-d) Six
hours after carrageenan injection, the animals were sacrificed and total RNA was extracted from subcutaneous connective tissue of carrageenan-
injected and control paw. IL-6, TNFa and inducible nitric oxide synthase (iNOS) mRNA were determined by RT-PCR. The results were normalized
against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA and mRNA levels in carrageenan-treated paw were compared to those in
control paw. Values are mean + SEM (n = 5 to 7). *P <0.05 and **P <0.01 as compared to mice treated with carrageenan alone.
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arthritis in rats. However, less is known about the possi-
ble effects of PPARa agonists in inflammation models.
Okamoto et al. [12] showed that fenofibrate decreased
signs of arthritis and, to a lesser extent, paw oedema in
Freund’s adjuvant-induced arthritis in rats.
In the present study, we extend the previous data by
showing that muraglitazar significantly decreased carra-
geenan-induced paw inflammation in mice. Carragee-
nan-induced paw oedema is a widely used model in
inflammation research. It represents features of acute
inflammation and innate immune responses and is use-
ful for primary screening of therapeutic efficacy of novel
anti-inflammatory agents [27]. Carrageenan-induced
inflammation has been described to occur in two phases.
The first and short-lasting phase starts almost immedi-
ately after the injection of carrageenan. The inflamma-
tion during this phase is local and the most abundant
mediators are histamine, serotonin and kinins. The sec-
ond phase starts in one to two hours after carrageenan
injection and has been described to involve the activa-
tion of inflammatory cells, including macrophages. The
expression of iNOS and COX-2, and the synthesis of
prostaglandins, oxygen-derived free radicals, TNFa, IL-
1b and IL-6 are increased in the inflamed tissue [28-30].
In our experiments, muraglitazar did not reduce paw
oedema at early time points, that is, during the first
phase of inflammation, while the anti-inflammatory
effects at later time points were clear. The results of the
effects of muraglitazar on paw oedema and inflamma-
tory gene expression in mice are in line with our results
in vitro, where muraglitazar reduced the production of
NO, IL-6 and TNFa and the expression of iNOS. These
results show that muraglitazar has anti-inflammatory
potency also in vivo.
During the last years the safety aspects of PPAR ago-
nists have been discussed. Rosiglitazone was withdrawn
from the market in Europe in September 2010, since it
had been found to increase the risk of myocardial
infarction in diabetic patients [31]. Fibrates, on the
other hand, were suggested to increase the risk of myo-
pathy, hepatotoxicity, cholecystitis and deep venous
thrombosis [32]. However, in detailed studies, the
increased risk of myocardial infarction has specifically
been linked to rosiglitazone [33], while the other thiazo-
lidinedione on the market, pioglitazone, seems to be a
rather safe drug [34,35]. In addition, fibrates did not
show increased risk of serious drug-related adverse
events in a recently published meta-analysis when they
were used as a monotherapy for the treatment of dysli-
pidemia [36]. Thus, it seems so far that the side effects
of PPAR agonists are compound-dependent and not
associated with the mechanism of action, and the advan-
tages of these drugs in diabetes and dyslipidemia are
markedly greater than the possible disadvantages.
Muraglitazar has been reported to have similar cardio-
vascular side effects as rosiglitazone, at least when com-
bined with sulfonylureas or metformin [37]. Because of
the adverse effects, muraglitazar’s developer Bristol-
Myers Squibb decided to discontinue further develop-
ment of the drug in May 2006. Nevertheless, although
the safety data published need to be considered, it is
worth noticing that only little knowledge of using mura-
glitazar in nondiabetic patients is available. Thus, further
studies are needed to establish the safety of muraglitazar
and other dual PPARg/a agonists in other possible indi-
cations than diabetes.
The connection between metabolism and inflamma-
tion is interesting and there is lots of research activity
going on in that area at this time. As many studies have
already suggested, PPARs might be an important link
between these two complex systems, and as shown in
the present study, PPAR agonists have anti-inflamma-
tory properties in classical inflammatory models. It has
been shown that a good treatment of metabolic diseases
reduces the low-grade inflammation associated with
obesity [38]. But could the modification of metabolic
pathways reduce the inflammatory responses associated
to classical inflammatory diseases? This is a question we
will be interested in answering in the future.
Conclusions
The present study shows that muraglitazar has several
anti-inflammatory effects in activated macrophages and
in carrageenan-induced inflammation in the mouse,
reflecting its activity on both PPARa and PPARg. The
results strengthen the previous evidence of the connec-
tion of metabolism and inflammation. Understanding
this connection in more detail might open a new avenue
in the treatment of chronic inflammatory diseases in the
future.
Abbreviations
CMC: carboxymethyl cellulose; DMSO: dimethyl sulfoxide; EI: electron
ionization; ESI: electrospray ion source; FTICR: Fourier transform ion cyclotron
resonance; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; IL-6:
interleukin 6; iNOS: inducible nitric oxide synthase; L-NIL: N6-(1-iminoethyl)-L-
lysine; LPS: lipopolysaccharide; NF-κB: nuclear factor kappa B; NO: nitric
oxide; PDTC: pyrrolidine dithiocarbamate; PPAR: peroxisome proliferator-
activated receptor; SEM: standard error of mean; TBS: tri-buffered saline;
TNFα: tumour necrosis factor α; TZDs: thiazolidinediones
Authors’ contributions
EP carried out most of the experiments, participated in the design of the
study and interpretation of the results, and drafted the manuscript. TL and
ML participated in the experimental analyses and design of the study. MFY
and MZA carried out the first series (Figure 7) of the in vivo assays. AK and
PHA synthesized muraglitazar. EM conceived and coordinated the study, and
supervised its design and conduction and writing of the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Paukkeri et al. Arthritis Research & Therapy 2013, 15:R51
http://arthritis-research.com/content/15/2/R51
Page 13 of 15
Acknowledgements
Ms. Meiju Kukkonen, Mrs. Salla Hietakangas and Ms. Petra Miikkulainen are
acknowledged for their excellent technical assistance and Mrs. Heli Määttä
for her skillful secretarial help. This study was supported by grants from the
Academy of Finland, the Medical Research Fund of Tampere University
Hospital and the Rheumatology Research Foundation. EP is a student in the
national FinPharma doctoral program.
Author details
1The Immunopharmacology Research Group, University of Tampere School
of Medicine and Tampere University Hospital, Medisiinarinkatu 3, Tampere,
FI-33014, Finland. 2School of Pharmaceutical Sciences, Universiti Sains
Malaysia, Minden, MY-11800, Pulau Pinang, Malaysia. 3Department of
Chemistry, University of Eastern Finland, Joensuu Campus, Yliopistokatu 7,
Joensuu, FI-80101, Finland.
Received: 20 August 2012 Revised: 14 February 2013
Accepted: 9 April 2013 Published: 17 April 2013
References
1. Hamilton JA, Tak PP: The dynamics of macrophage lineage populations
in inflammatory and autoimmune diseases. Arthritis Rheum 2009,
60:1210-1221.
2. Gierut A, Perlman H, Pope RM: Innate immunity and rheumatoid arthritis.
Rheum Dis Clin North Am 2010, 36:271-296.
3. Zeyda M, Stulnig TM: Adipose tissue macrophages. Immunol Lett 2007,
112:61-67.
4. Schenk S, Saberi M, Olefsky JM: Insulin sensitivity: modulation by nutrients
and inflammation. J Clin Invest 2008, 118:2992-3002.
5. Mathieu P, Lemieux I, Despres JP: Obesity, inflammation, and
cardiovascular risk. Clin Pharmacol Ther 2010, 87:407-416.
6. Lago F, Dieguez C, Gomez-Reino J, Gualillo O: Adipokines as emerging
mediators of immune response and inflammation. Nat Clin Pract
Rheumatol 2007, 3:716-724.
7. Shapiro H, Lutaty A, Ariel A: Macrophages, meta-inflammation, and
immuno-metabolism. ScientificWorldJournal 2011, 11:2509-2529.
8. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003,
3:23-35.
9. Fruchart JC: Peroxisome proliferator-activated receptor-alpha (PPARα): At
the crossroads of obesity, diabetes and cardiovascular disease.
Atherosclerosis 2009, 205:1-8.
10. Fuentes L, Roszer T, Ricote M: Inflammatory mediators and insulin
resistance in obesity: role of nuclear receptor signaling in macrophages.
Mediators Inflamm 2010, 2010:219583.
11. Giaginis C, Giagini A, Theocharis S: Peroxisome proliferator-activated
receptor-γ (PPAR-γ) ligands as potential therapeutic agents to treat
arthritis. Pharmacol Res 2009, 60:160-169.
12. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N:
Inhibition of NF-κB signaling by fenofibrate, a peroxisome proliferator-
activated receptor-α ligand, presents a therapeutic strategy for
rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:323-330.
13. Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M,
Farrelly D, Golla R, Grover G, Harrity T, Ma Z, Moore L, Ren J, Seethala R,
Cheng L, Sleph P, Sun W, Tieman A, Wetterau JR, Doweyko A,
Chandrasena G, Chang SY, Humphreys WG, Sasseville VG, Biller SA,
Ryono DE, Selan F, Hariharan N, Cheng PT: Design and synthesis of N-[(4-
Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)
ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel
peroxisome proliferator-activated receptor α/γ dual agonist with
efficacious glucose and lipid-lowering activities. J Med Chem 2005,
48:2248-2250.
14. Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R,
Shockey G, Davidson JA: Muraglitazar, a dual (α/γ) PPAR activator: a
randomized double-blind, placebo-controlled, 24-week monotherapy
trial in adult patients with type 2 diabetes. Clin Ther 2005, 27:1181-1195.
15. Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J,
Norwood P, O’Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT,
DeFronzo RA: Improvement of glycemic control, triglycerides, and HDL
cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-
activated receptor activator, in patients with type 2 diabetes
inadequately controlled with metformin monotherapy. Diabetes Care
2006, 29:1016-1023.
16. Kleinert H, Euchenhofer C, Ihrig-Biedert I, Förstermann U: Glucocorticoids
inhibit the induction of nitric oxide synthase II by down-regulating
cytokine-induced activity of transcription factor nuclear factor-κB. Mol
Pharmacol 1996, 4:15-21.
17. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS,
Tannenbaum SR: Analysis of nitrate, nitrite, and [15N]nitrate in biological
fluids. Anal Biochem 1982, 126:131-138.
18. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 7:248-254.
19. Paukkeri EL, Leppänen T, Sareila O, Vuolteenaho K, Kankaanranta H,
Moilanen E: PPARα agonists inhibit nitric oxide production by enhancing
iNOS degradation in LPS-treated macrophages. Br J Pharmacol 2007,
152:1081-1091.
20. Kleinert H, Schwarz PM, Föstermann U: Regulation of the expression of
inducible nitric oxide synthase. Biol Chem 2003, 384:1343-1364.
21. Brown KD, Claudio E, Siebenlist U: The roles of the classical and
alternative nuclear factor-κB pathways: potential implications for
autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008, 10:212.
22. Moraes LA, Piqueras L, Bishop-Bailey D: Peroxisome proliferator-activated
receptors and inflammation. Pharmacol Ther 2006, 110:371-385.
23. Libby P, Plutzky J: Inflammation in diabetes mellitus: role of peroxisome
proliferator-activated receptor-α and peroxisome proliferator-activated
receptor-γ agonists. Am J Cardiol 2007, 99:27B-40B.
24. Tomita T, Kakiuchi Y, Tsao PS: THR0921, a novel peroxisome proliferator-
activated receptor gamma agonist, reduces the severity of collagen-
induced arthritis. Arthritis Res Ther 2006, 8:R7.
25. Sumariwalla PF, Palmer CD, Pickford LB, Feldmann M, Foxwell BM,
Brennan FM: Suppression of tumour necrosis factor production from
mononuclear cells by a novel synthetic compound, CLX-090717.
Rheumatology 2009, 48:32-38.
26. Koufany M, Moulin D, Bianchi A, Muresan M, Sebillaud S, Netter P,
Weryha G, Jouzeau JY: Anti-inflammatory effect of antidiabetic
thiazolidinediones prevents bone resorption rather than cartilage
changes in experimental polyarthritis. Arthritis Res Ther 2008, 10:R6.
27. Paw edema. In Drug discovery and Evaluation: Pharmacological Assays.. 2
edition. Edited by: Vogel HG. New York: Springer; 2002:759-762.
28. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT,
Currie MG: Nitric oxide: a key mediator in the early and late phase of
carrageenan-induced rat paw inflammation. Br J Pharmacol 1996,
118:829-838.
29. Loram LC, Fuller A, Fick LG, Cartmell T, Poole S, Mitchell D: Cytokine
profiles during carrageenan-induced inflammatory hyperalgesia in rat
muscle and hind paw. J Pain 2007, 8:127-136.
30. Morris CJ: Carrageenan-induced paw edema in the rat and mouse.
Methods Mol Biol 2003, 225:115-121.
31. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med 2007,
356:2457-2471.
32. Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety considerations
with fibrate therapy. Am J Cardiol 2007, 99:3C-18C.
33. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M,
Jones NP, Komajda M, McMurray JJ, RECORD Study Team: Rosiglitazone
evaluated for cardiovascular outcomes in oral agent combination
therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-
label trial. Lancet 2009, 373:2125-2135.
34. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of
cardiovascular events in patients with type 2 diabetes mellitus: a meta-
analysis of randomized trials. JAMA 2007, 298:1180-1188.
35. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, PROactive
investigators: Safety and tolerability of pioglitazone in high-risk patients
with type 2 diabetes. Drug Saf 2009, 32:187-202.
36. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A,
Chalmers J, Perkovic V: Effects of fibrates on cardiovascular outcomes: a
systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
37. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major
adverse cardiovascular events in patients with type 2 diabetes mellitus.
JAMA 2005, 294:2581-2586.
Paukkeri et al. Arthritis Research & Therapy 2013, 15:R51
http://arthritis-research.com/content/15/2/R51
Page 14 of 15
38. Kontunen P, Vuolteenaho K, Nieminen R, Lehtimaki L, Kautiainen H,
Kesaniemi Y, Ukkola O, Kauppi M, Hakala M, Moilanen E: Resistin is linked
to inflammation, and leptin to metabolic syndrome, in women with
inflammatory arthritis. Scand J Rheumatol 2011, 40:256-262.
doi:10.1186/ar4211
Cite this article as: Paukkeri et al.: Anti-inflammatory properties of a
dual PPARgamma/alpha agonist muraglitazar in in vitro and in vivo
models. Arthritis Research & Therapy 2013 15:R51.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Paukkeri et al. Arthritis Research & Therapy 2013, 15:R51
http://arthritis-research.com/content/15/2/R51
Page 15 of 15
